Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) fell 1.5% on Thursday . The stock traded as low as $57.48 and last traded at $58.84, with a volume of 148,112 shares traded. The stock had previously closed at $59.75.

Several brokerages have weighed in on EGRX. Mizuho cut Eagle Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $66.00 to $47.00 in a research note on Monday, June 20th. TheStreet raised Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 9th. Royal Bank Of Canada reduced their price objective on Eagle Pharmaceuticals from $94.00 to $78.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 10th. Finally, Zacks Investment Research raised Eagle Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, July 4th. One analyst has rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. Eagle Pharmaceuticals has an average rating of “Buy” and a consensus target price of $91.94.

The firm has a market cap of $943.48 million and a PE ratio of 309.44. The company’s 50-day moving average price is $53.61 and its 200-day moving average price is $48.10.

Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.71 by $0.09. The firm had revenue of $40.90 million for the quarter, compared to analysts’ expectations of $43.55 million. The company’s revenue was up 581.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.53) earnings per share. Equities analysts forecast that Eagle Pharmaceuticals Inc. will post $3.21 EPS for the current year.

In other news, major shareholder Proquest Investments Iv, L.P. sold 28,870 shares of the stock in a transaction dated Wednesday, August 24th. The shares were sold at an average price of $63.00, for a total transaction of $1,818,810.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

A hedge fund recently raised its stake in Eagle Pharmaceuticals stock. Bank of Montreal Can increased its position in shares of Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) by 62.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 119,902 shares of the specialty pharmaceutical company’s stock after buying an additional 46,020 shares during the period. Bank of Montreal Can owned 0.77% of Eagle Pharmaceuticals worth $10,632,000 as of its most recent filing with the SEC.

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.